Close

Drug Research

Kite and Oxford BioTherapeutics Establish Cell Therapy Research Collaboration in Blood Cancers and Solid Tumors

Kite, a Gilead Company, and Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (IO) and antibody-drug conjugate (ADC)-based therapies, announced that the companies have entered into a research collaboration to evaluate five novel...

Servier and X-Chem Announce Drug Discovery Collaboration in Neurological Diseases

Servier, a global pharmaceutical Group and X-Chem, Inc., a privately held drug discovery company announced a partnership to identify and develop novel small molecules for the treatment of neurological disorders. Under the terms of the multi-target agreement, X-Chem will utilize...

WuXi STA’s Integrated CMC Platform Supports InnoCare Orelabrutinib Approved by NMPA

STA Pharmaceutical, a WuXi AppTec Company (WuXi STA), announces their partner Innocare has received approval by the National Medical Products Administration of China (NMPA) for Orelabrutinib. Under the Marketing Authorization Holder (MAH) policy, WuXi STA provided an integrated and...

INOVIO, Advaccine Enter Exclusive COVID-19 DNA Vax Pact

INOVIO, a biotechnology company focused on precisely designed DNA medicines to treat and prevent infectious diseases and cancer, and Advaccine Biopharmaceuticals Suzhou, an emerging biotech company with next-gen technology in vaccines, have entered into a collaboration and license agreement...

Incyte and Cellenkos Enter into Global Development Collaboration Agreement for CK0804

Incyte and Cellenkos, Inc., a privately held, clinical stage biotech company, announced a development collaboration to investigate the combination of ruxolitinib (Jakafi®) and CK0804, Cellenkos’ cryopreserved CXCR4 enriched, allogeneic, umbilical cord blood-derived T-regulatory cells, in patients with myelofibrosis (MF)....

Moderna Provides COVID-19 Vaccine Supply Update

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, provided a supply update for the Moderna COVID-19 Vaccine, increasing its base-case global production estimate from 500 to 600 million doses for 2021. Moderna said it is...

Treating brain disorders with new nanoparticle drug delivery system

A new nanoparticle drug-delivery system could help scientists overcome the long-standing problem of delivering therapeutics across the blood-brain barrier and into the brain. Progress has been made over the past few decades in identifying biological pathways that lead to neurodegenerative...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read